圣马力诺生物技术集团完成了改组,根据两年计划,将Carragelos出售给Unsher。 Marinomed Biotech AG completes restructuring, sells Carragelose to Unither, under two-year plan.

圣马力诺生物技术集团成功地完成了改组工作,改组工作于2024年8月开始,经过科勒纽堡法院的批准以及包括欧洲投资银行在内的全体债权人的一致协议。 Marinomed Biotech AG has successfully completed its restructuring, which began in August 2024, following approval from the Korneuburg court and unanimous creditor agreement, including the European Investment Bank. 该计划的关键是将其Carragelos业务出售给Unther制药公司,12月经股东批准。 Key to the plan is the sale of its Carragelose business to Unither Pharmaceuticals, approved by shareholders in December. 公司必须在两年内满足所有条件。 The company must meet all conditions within two years.